A review of imaging agent development.
This educational review highlights the processes, opportunities, and challenges encountered in the discovery and development of imaging agents, mainly positron emission tomography and single-photon emission computed tomography tracers. While the development of imaging agents parallels the drug development process, unique criteria are needed to identify opportunities for new agents. Imaging agent development has the flexibility to pursue functional or nonfunctional targets as long as they play a role in the specific disease or mechanism of interest and meet imageability requirements. However, their innovation is tempered by relatively small markets for diagnostic imaging agents, intellectual property challenges, radiolabeling constraints, and adequate target concentrations for imaging. At the same time, preclinical imaging is becoming a key translational tool for proof of mechanism and concept studies. Pharmaceutical and imaging industries face a common bottleneck in the form of the limited number of trials one company can possibly perform. However, microdosing and theranostics are evidence that partnerships between pharmaceutical and imaging companies can accelerate clinical translation of tracers and therapeutic interventions. This manuscript will comment on these aspects to provide an educational review of the discovery and development processes for imaging agents.
Medical, Science, and Technology Office, GE Healthcare, 101 Carnegie Center, Princeton, New Jersey 08540, USA.
Eric D
ED
Agdeppa
Mary E
ME
Spilker
D000818:Animals; D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000138:chemical synthesis / Q000737:chemistry; D003952:Diagnostic Imaging / Q000639:trends*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008967:Molecular Biology
D003287:Contrast Media